Inactive Instrument

News CELLCEUTIX OTC Bulletin Board

Stocks

CTIX

US15115V1017

Biotechnology & Medical Research

End-of-day quote OTC Bulletin Board Other stock markets
- ^USD	-

24-02-01	Innovation Pharmaceuticals Inc. Announces Resignation of Board Members	CI
23-12-05	Alfasigma S.p.A. and Innovation Pharmaceuticals Inc. Terminate Exclusive License Agreement	CI

All News

Mentions Relevance

24-02-01	Innovation Pharmaceuticals Inc. Announces Resignation of Board Members	CI
23-12-05	Alfasigma S.p.A. and Innovation Pharmaceuticals Inc. Terminate Exclusive License Agreement	CI
23-11-20	Innovation Pharmaceuticals Inc. Reports Earnings Results for the First Quarter Ended September 30, 2023	CI
23-09-28	Innovation Pharmaceuticals Inc. Reports Earnings Results for the Full Year Ended June 30, 2023	CI
23-08-28	Innovation Pharmaceuticals Announces New Milestone at BeaMed; On Track to File 510(k) Submission to FDA in Q2 2024	AQ
23-06-21	Innovation Pharmaceuticals Provides Update on U.S. Patent Applications Covering Use of Brilacidin in Inflammatory Bowel Diseases, Coronaviruses and Fungal Diseases	CI
23-06-21	Innovation Pharmaceuticals Provides Update on U.S. Patent Applications Covering Use of Brilacidin in Inflammatory Bowel Diseases, Coronaviruses and Fungal Diseases	AQ
23-06-05	Innovation Pharma Announces BeaMed Technologies Breakthrough in Development of Fiber Optic Probes for StingRay Laser System; Paves Way for Groundbreaking Integration Testing	AQ
23-05-15	Innovation Pharmaceuticals Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended March 31, 2023	CI
23-04-17	Innovation Pharmaceuticals Brilacidin Antifungal Research Published in Nature Communications	AQ
23-03-15	Innovation Pharmaceuticals Announces New Antifungal Testing of Brilacidin by NIH/NIAID-Affiliated and Other Academic Researchers	AQ
23-03-15	Innovation Pharmaceuticals Announces New Antifungal Testing of Brilacidin by NIH/NIAID Affiliated and Other Academic Researchers	CI
23-02-23	Innovation Pharmaceuticals Visits BeaMed; New StingRay Laser System for Epilepsy and Brain Tumors Moving Toward FDA Submission	AQ
23-02-15	INNOVATION PHARMACEUTICALS INC. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS (form 10-Q)	AQ
23-02-15	Innovation Pharmaceuticals Inc. Reports Earnings Results for the Second Quarter and Six Months Ended December 31, 2022	CI
23-01-09	Innovation Pharmaceuticals Announces BT BeaMedical Technologies and Shina Systems Ltd. Enter into a Definitive Strategic Development Agreement	AQ
23-01-04	INNOVATION PHARMACEUTICALS INC. : Other Events (form 8-K)	AQ
22-12-14	Innovation Pharmaceuticals Reports New In Vivo Antifungal Data Showing Brilacidin's Potential for Treating Fungal Keratitis	AQ
22-12-13	Innovation Pharmaceuticals Reports New In Vivo Antifungal Data Showing Brilacidin’s Potential for Treating Fungal Keratitis	AQ
22-12-13	Innovation Pharmaceuticals Provides an Update on Ongoing Research on the Broad-Spectrum Antifungal Activity of Brilacidin	CI
22-11-28	Innovation Pharmaceuticals Announces BT BeaMedical Technologies Receives FDA Clearance for New Surgical Laser Family	AQ
22-11-16	Scientific Poster on Innovation Pharmaceuticals Brilacidin to be Presented at 2022 Chemical and Biological Defense Science & Technology Conference	AQ
22-11-10	INNOVATION PHARMACEUTICALS INC. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS (form 10-Q)	AQ
22-11-10	Innovation Pharmaceuticals Inc. Reports Earnings Results for the First Quarter Ended September 30, 2022	CI
22-10-27	Innovation Pharmaceuticals - NHS Medical Director for Specialised Services Calls New Laser Technology for Epilepsy 'Game-Changing Breakthrough'	AQ